Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma

被引:5
作者
Carr, Rebecca A. [1 ]
Hsu, Meier [2 ]
Harrington, Caitlin A. [1 ]
Tan, Kay See [2 ]
Bains, Manjit S. [1 ]
Bott, Matthew J. [1 ]
Ilson, David H. [3 ]
Isbell, James M. [1 ]
Janjigian, Yelena Y. [3 ]
Maron, Steven B. [3 ]
Park, Bernard J. [1 ]
Rusch, Valerie W. [1 ]
Sihag, Smita [1 ]
Wu, Abraham J. [4 ]
Jones, David R. [1 ]
Ku, Geoffrey Y. [3 ]
Molena, Daniela [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
CROSS regimen; esophageal adenocarcinoma; FOLFOX; induction; positron emission tomography-directed chemoradiation; COMPLETE PATHOLOGICAL RESPONSE; ESOPHAGOGASTRIC JUNCTION; PREOPERATIVE CHEMORADIOTHERAPY; NEOADJUVANT CHEMORADIOTHERAPY; TUMOR-REGRESSION; SURVIVAL; CHEMOTHERAPY; CANCER; CARCINOMA; THERAPY;
D O I
10.1097/SLA.0000000000005163
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: To compare the efficacy and safety of induction FOLFOX followed by PET-directed nCRT, induction CP followed by PET-directed nCRT, and nCRT with CP alone in patients with EAC. Summary of Background Data: nCRT with CP is a standard treatment for locally advanced EAC. The results of cancer and leukemia group B 80803 support the use of induction chemotherapy followed by PET-directed chemo-radiation therapy. Methods: We retrospectively identified all patients with EAC who underwent the treatments above followed by esophagectomy. We assessed incidences of pathologic complete response (pCR), near-pCR (ypN0 with >= 90% response), and surgical complications between treatment groups using Fisher exact test and logistic regression; disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method and evaluated using the log-rank test and extended Cox regression. Results: In total, 451 patients were included: 309 (69%) received induction chemotherapy before nCRT (FOLFOX, n = 70; CP, n = 239); 142 (31%) received nCRT with CP. Rates of pCR (33% vs. 16%, P = 0.004), near-pCR (57% vs. 33%, P < 0.001), and 2-year DFS (68% vs. 50%, P = 0.01) were higher in the induction FOLFOX group than in the induction CP group. Similarly, the rate of near-pCR (57% vs. 42%, P = 0.04) and 2-year DFS (68% vs. 44%, P < 0.001) were significantly higher in the FOLFOX group than in the no-induction group. Conclusions: Induction FOLFOX followed by PET-directed nCRT may result in better histopathologic response rates and DFS than either induction CP plus PET-directed nCRT or nCRT with CP alone.
引用
收藏
页码:E538 / E544
页数:7
相关论文
共 27 条
[1]   A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer [J].
Ajani, J. A. ;
Xiao, L. ;
Roth, J. A. ;
Hofstetter, W. L. ;
Walsh, G. ;
Komaki, R. ;
Liao, Z. ;
Rice, D. C. ;
Vaporciyan, A. A. ;
Maru, D. M. ;
Lee, J. H. ;
Bhutani, M. S. ;
Eid, A. ;
Yao, J. C. ;
Phan, A. P. ;
Halpin, A. ;
Suzuki, A. ;
Taketa, T. ;
Thall, P. F. ;
Swisher, S. G. .
ANNALS OF ONCOLOGY, 2013, 24 (11) :2844-2849
[2]  
Allison P. D., 1995, Survival analysis using SAS: A practical guide
[3]  
Amin M., 2017, AJCC Cancer Staging Manual, Veighth
[4]   Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival [J].
Berger, AC ;
Farma, J ;
Scott, WJ ;
Freedman, G ;
Weiner, L ;
Cheng, JD ;
Wang, H ;
Goldberg, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4330-4337
[5]   Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy [J].
Chevrollier, Guillaume S. ;
Giugliano, Danica N. ;
Palazzo, Francesco ;
Keith, Scott W. ;
Rosato, Ernest L. ;
Evans, Nathaniel R., III ;
Berger, Adam C. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2020, 24 (02) :288-298
[6]   Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation [J].
Chirieac, LR ;
Swisher, SG ;
Ajani, JA ;
Komaki, RR ;
Correa, AM ;
Morris, JS ;
Roth, JA ;
Rashid, A ;
Hamilton, SR ;
Wu, TT .
CANCER, 2005, 103 (07) :1347-1355
[7]   The Clavien-Dindo Classification of Surgical Complications Five-Year Experience [J].
Clavien, Pierre A. ;
Barkun, Jeffrey ;
de Oliveira, Michelle L. ;
Vauthey, Jean Nicolas ;
Dindo, Daniel ;
Schulick, Richard D. ;
de Santibanes, Eduardo ;
Pekolj, Juan ;
Slankamenac, Ksenija ;
Bassi, Claudio ;
Graf, Rolf ;
Vonlanthen, Rene ;
Padbury, Robert ;
Cameron, John L. ;
Makuuchi, Masatoshi .
ANNALS OF SURGERY, 2009, 250 (02) :187-196
[8]   Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy [J].
Dittrick, George W. ;
Weber, Jill M. ;
Shridhar, Ravi ;
Hoffe, Sarah ;
Melis, Marcovalerio ;
Almhanna, Khaldoun ;
Barthel, James ;
McLoughlin, James ;
Karl, Richard C. ;
Meredith, Kenneth L. .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (05) :1678-1684
[9]   Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival [J].
Donahue, James M. ;
Nichols, Francis C. ;
Li, Zhuo ;
Schomas, David A. ;
Allen, Mark S. ;
Cassivi, Stephen D. ;
Jatoi, Aminah ;
Miller, Robert C. ;
Wigle, Dennis A. ;
Shen, K. Robert ;
Deschamps, Claude .
ANNALS OF THORACIC SURGERY, 2009, 87 (02) :392-399
[10]   Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. [J].
Goodman, Karyn A. ;
Niedzwiecki, Donna ;
Hall, Nathan ;
Bekaii-Saab, Tanios S. ;
Ye, Xing ;
Meyers, Michael O. ;
Mitchell-Richards, Kisha ;
Boffa, Daniel J. ;
Frankel, Wendy L. ;
Venook, Alan P. ;
Hochster, Howard S. ;
Crane, Christopher H. ;
O'Reilly, Eileen Mary ;
Ilson, David H. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)